These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24914480)

  • 1. Efficacy of colestilan in the treatment of hyperphosphataemia in renal disease patients.
    Locatelli F; Dimkovic N; Spasovski G
    Expert Opin Pharmacother; 2014 Jul; 15(10):1475-88. PubMed ID: 24914480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study.
    Locatelli F; Spasovski G; Dimkovic N; Wanner C; Dellanna F; Pontoriero G
    Nephrol Dial Transplant; 2014 May; 29(5):1061-73. PubMed ID: 24302608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo-controlled, multiple fixed-dose trial.
    Locatelli F; Dimkovic N; Spasovski G
    Nephrol Dial Transplant; 2013 Jul; 28(7):1874-88. PubMed ID: 23610100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles.
    Locatelli F; Del Vecchio L; Violo L; Pontoriero G
    Expert Opin Drug Saf; 2014 May; 13(5):551-61. PubMed ID: 24702470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, Double-Blind, Placebo-Controlled, Withdrawal Study of Colestilan after Dose Titration in Chronic Kidney Disease Dialysis Patients with Hyperphosphatemia.
    Hertel J; Locatelli F; Spasovski G; Dimkovic N; Wanner C
    Nephron; 2015; 130(4):229-38. PubMed ID: 26184491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of phosphate binders in chronic kidney disease.
    Ketteler M; Biggar PH
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperphosphataemia: treatment options.
    Malberti F
    Drugs; 2013 May; 73(7):673-88. PubMed ID: 23625273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colestilan for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis.
    Locatelli F; Dimkovic N; Spasovski G
    Expert Rev Endocrinol Metab; 2015 Mar; 10(2):131-142. PubMed ID: 30293511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Evaluation of Colestilan in Chronic Kidney Disease Stage 5 Dialysis Patients with Hyperphosphataemia.
    Locatelli F; Spasovski G; Dimkovic N; Wanner C
    Blood Purif; 2016; 41(4):247-53. PubMed ID: 26670307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L; Bernard LM; Elder GJ
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and potential treatment options for hyperphosphatemia.
    Carfagna F; Del Vecchio L; Pontoriero G; Locatelli F
    Expert Opin Drug Saf; 2018 Jun; 17(6):597-607. PubMed ID: 29783873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Efficacy and Safety of Phosphate Binders in Hyperphosphatemia Patients With Chronic Kidney Disease.
    Yang X; Bai Q; Li Y; Liu H; Guo H; Zhang X
    JPEN J Parenter Enteral Nutr; 2018 May; 42(4):766-777. PubMed ID: 28777915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular mortality in chronic kidney disease patients: potential mechanisms and possibilities of inhibition by resin-based phosphate binders.
    Locatelli F; Del Vecchio L
    Expert Rev Cardiovasc Ther; 2015 May; 13(5):489-99. PubMed ID: 25804298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of hyperphosphataemia in dialysis patients: role of phosphate binders in the elderly.
    Lorenzo Sellares V; Torres Ramírez A
    Drugs Aging; 2004; 21(3):153-65. PubMed ID: 14979734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal use of phosphate binders in chronic kidney disease.
    Sonikian M; Papachristou E; Goumenos DS
    Expert Opin Pharmacother; 2013 Dec; 14(18):2521-32. PubMed ID: 24215605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in pharmacotherapy for hyperphosphatemia in renal disease.
    Spasovski G
    Expert Opin Pharmacother; 2015; 16(17):2589-99. PubMed ID: 26374200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of colestilan on serum phosphorus in dialysis patients: A meta-analysis of the literature.
    Zhang Q; Li M; Chen J
    Nephrology (Carlton); 2016 Mar; 21(3):229-35. PubMed ID: 26272343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphate binders in CKD: chalking out the differences.
    Rees L; Shroff RC
    Pediatr Nephrol; 2010 Mar; 25(3):385-94. PubMed ID: 19898877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphate binders in chronic kidney disease: an updated narrative review of recent data.
    Floege J
    J Nephrol; 2020 Jun; 33(3):497-508. PubMed ID: 31865608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.